 |
 |
Synta Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing, and commercializing novel pharmaceutical products for extending and
enhancing the lives of patients with severe medical conditions, including
cancer and chronic inflammatory disease. Synta has a unique chemical compound
library, an integrated discovery engine, and a diverse pipeline of clinical-
and preclinical-stage drug candidates with distinct mechanisms of action and
novel chemical structures. All clinical candidates were invented internally by
Synta scientists using our compound library and discovery capabilities
Synta: big pharma assets, small pharma speed
-
Mechanism diversity and pipeline depth: Synta has three programs in
clinical development, two programs in preclinical development, and additional
programs in discovery. Each program represents a distinct chemical family,
mechanism of action, and therapeutic opportunity. We actively develop second or
third generation compounds for each program to ensure strong IP protection and
competitive positioning.
-
High quality clinical data: We run double-blind, randomized, controlled,
multi-center Phase 2b and Phase 3 trials whenever practical and appropriate. We
believe the rigorous safety and efficacy data we generate earlier in
development lead to better decision making and resource allocation later in
development.
-
Productive discovery engine and chemistry platform: Our unique chemical
compound library – proprietary compounds collected over two decades from
industrial and academic sources not typically found at pharmaceutical firms –
combined with our high throughput screening and in vivo modeling capabilities;
our medicinal, computational, analytic, and process-development chemistry
expertise; and our in vitro and in vivo toxicology and DMPK experience allow us
to continue to generate promising new drug candidates each year, and set high
standards for those compounds we choose to advance into clinical trials.
-
Strong financial and strategic position: Our cash position and the
financial and strategic benefits of having one partnered and four unpartnered
programs, each targeting large-market opportunities, together with a discovery
engine that can continue to generate promising new drug candidates each year,
provide a foundation for long-term, sustainable growth.
-
Strong intellectual property position: We have an extensive intellectual
property portfolio consisting of over 700 issued or pending patents. All Synta
compounds currently in clinical trials represent novel chemical structures
protected by issued or allowed composition of matter patents, as well as a
robust package of related structure, mechanism, formulation, manufacturing, and
administration patents.
-
Experienced management team: The Synta management team has deep
experience in all stages of drug discovery, development and commercialization.
In addition to developing our current pipeline from discovery through Phase 3,
including initiating and overseeing nearly two dozen clinical trials, the Synta
management team has collectively been involved in the pre-clinical development,
clinical development, and commercial launch of multiple leading drugs.
Synta combines the high-energy culture and exciting growth opportunities of a
new biotechnology company with the drug development assets and expertise of a
mature pharmaceutical organization.
Click here to view
the Corporate Fact Sheet.
|
 |
